Visiongain has published a new report entitled the Drug Discovery Outsourcing 2022-2032. It includes profiles of Drug Discovery Outsourcing and Forecasts Market Segment by Service Type (Chemical Services, Biology Services, Lead Optimization, Lead Identification & Screening, Others), by Molecule Type (Large Molecule Drugs, Small Molecule Drugs), by Therapeutic Area (Oncology, Infectious Disease, Central Nervous System, Immunology, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Others) PLUS COVID-19 Impact Analysis and Recovery Pattern Analysis (V-shaped, W-shaped, U-shaped, L-shaped) Profiles of Leading Companies, Region and Country.
The global vaccine contract manufacturing market was valued at US$9,241.9 million in 2021 and is projected to grow at a CAGR of 7.55% during the forecast period 2022-2032.
Growing Demand for Outsourced Services to Boost Market Growth
The market for drug discovery outsourcing is on the rise; it is growing to reach US$20,488.2 million in 2032. Over the next decade, global drug discovery outsourcing industry is projected to grow significantly at a CAGR of over 7%. As pharmaceutical corporations become increasingly capable of spreading the burden of high-risk/high-reward new drug research, there is a growing demand for outsourced services. Furthermore, patent expiry of several pharmaceutical drugs will seek to infuse drug pipelines with a new set of candidates. One of the fastest expanding segments of the pharmaceutical contract research industry is drug discovery outsourcing. Companies are outsourcing their discovery process due to rising costs in the discovery and development of novel pharmaceuticals. CROs have grown quickly to fulfil the demands of a wide range of businesses, from small to mid/large pharmaceutical firms. The trend shows that CROs are becoming the driving force behind the discovery of drugs. The North American region will dominate market, with Visiongain predicting strong competition from emerging markets in Asia-Pacific, such as China and India, over the forecast period.
Strong Growth Potentials Across Developed and Emerging Economies
Visiongain believes that the market for drug discovery has strong growth potentials in both the developed and emerging markets, leading to a more interlinked future for the pharmaceutical industry. Although expansion will depend on the continued focus of the pharmaceutical industry on drug pipeline replenishment, efforts by governments to improve healthcare provision and competition within the pharmaceutical industry.
Although many niche CROs are not in a position to enter into strategic partnerships with large pharmaceutical companies in terms of service capabilities, their specialized services will remain in demand throughout the forecast period. Small biotechnology companies are largely responsible for the discovery of drugs in the market, and those who do not want to out-licence their candidates for large pharma needs the capabilities of CROs to perform early discovery processes. Most small biotech companies may seek the expertise that smaller CROs can offer, seeking expertise in niche therapeutics areas or stages of development. Niche CROs will also benefit from the demand for services from larger CROs with limited or no capacity in particular areas of drug development. Although the number of contracts available to the drug discovery outsourcing industry continues to increase, there are many CROs competing for these contracts. Whereas once academic research laboratories were seen as competing with CROs because they could form partnerships with industrial companies, many CROs are now working with academic research laboratories to gather much of their drug discovery sources.
Download Exclusive Sample of Report
https://www.visiongain.com/report/drug-discovery-outsourcing-market-2022/#download_sampe_div
How has COVID-19 had a Significant Impact on the Drug Discovery Outsourcing Market?
Pharmaceutical businesses have been pushed into the spotlight as a result of the COVID-19 outbreak. Drug development is an expensive & time-consuming procedure. As a result, pharmaceutical and biotech corporations are turning to academia and private contract research organizations to outsource their research. Rising collaborations between public and commercial entities speed up drug discovery, resulting in a rise in worldwide demand for drug discovery outsourcing services. After the covid effect, this scenario is projected to continue. Companies have been asked to produce drugs that improve life expectancy due to an increase in chronic illness cases. According to the United Nations, adults over 65 are anticipated to live an additional 17 years between 2015 and 2020. Some of the key therapeutic areas where corporations are actively interested in outsourcing are oncology, cardiovascular, and anti-infectives.
How this Report Will Benefit you?
Visiongain’s 354 page report provides 122 tables and 150 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the global vaccine contract manufacturing market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Drug Discovery Outsourcing. Get the financial analysis of the overall market and different segments including type, process, upstream, downstream, company size and capture higher market share. We believe that high opportunity remains in this fast-growing vaccine contract manufacturing market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report would help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.
What are the Current Market Drivers?
Cost Reduction: A Central Driver for Outsourcing
One of the key drivers for outsourcing drug discovery operations is to lower operational costs. It is a fact of today’s difficult economic climate that companies are look at all possible options for trimming their operational budgets without comprising on the quality of the services they offer. Outsourcing has become such an indispensable tool that the majority of the leading pharmaceutical companies continue to outsource some aspect of their drug discovery operations.
In addition to the pharmaceutical industry, there is a growing client base of virtual pharmaceutical companies that outsource 100% of their work to CROs. Increasingly a large number of these virtual companies are being established because venture capital firms are reluctant to provide sufficient start-up funding to these companies for fear that the money may be squandered on a product that will not reach the clinical stage. Thus, cost is a central driver for outsourcing to contract research organizations.
Emerging Markets are a Popular Destination for CROs
Drug discovery outsourcing in the pharmaceutical industry has been operating for the last few decades. However, the global outsourcing market has grown considerably in recent years in response to the growing pressures felt by pharmaceutical companies. Outsourcing to China, India and South Korea are common practices as the CROs in these countries provide cheaper services owing to the reduced cost of labour and resources in Asia. Increasingly, some of the large CROs provide a range of services spanning from drug discovery to clinical trials support.
Download Exclusive Sample of Report
https://www.visiongain.com/report/drug-discovery-outsourcing-market-2022/#download_sampe_div
Where are the Market Opportunities?
Available Scope for the Expansion of CROs to Offer Lucrative Growth Prospects Through 2032
Contract research organizations have seen growth previously been driven by a number of factors. Growth has occurred as a result of the addition of new customers. However, CROs have also expanded through the acquisition of other smaller CROs offering a particular expertise, or the acquisition of new facilities.
Technological advances in areas such as molecular biology have stimulated the expansion of niche CROs, providing expertise in particular services. CRO growth and expansion will be a continuing trend throughout the forecast period. Companies will look to expand in a variety of ways- adding new services that meet changing demands from the pharmaceutical industry, expanding into new territories, or simply adding capacity for larger projects. There are always some form of risks related with all forms of expansion. However, Visiongain believes that the major market players that expand through a combination of these ways will be best-placed towards the end of this decade.
Advancement in Targeted Therapies to Offer Lucrative Opportunities for Market Players
The use of genetic analysis to get a better knowledge of disease biology has resulted in the identification of various subgroups of patients within a disease. Companies are already developing novel therapies for these subgroups of patients, aiming for a smaller patient population but higher-priced medications. A comparable trend is the discovery of medications for orphan diseases, which are uncommon diseases with significant unmet medical needs. CROs have both possibilities and problems as a result of such trends. According to reports, there are almost three times as many medications in the pipeline for rare illnesses now as there were ten years ago. Rare illnesses will be addressed by 1,800 of the more than 8,500 new medications under development.
Competitive Landscape
The major players operating in the vaccine contract manufacturing market are Curia Global, Inc., Charles River Laboratories, Dalton Pharma, Domainex, Eurofins, Evotec AG, Genscript, Aragen Life Sciences Pvt. Ltd. (GVK Biosciences), Jubilant Biosys Ltd., Laboratory Corporation of America Holdings, Pharmaron, QIAGEN N.V., Selvita, Sundia Meditech Co Ltd., Sygnature Discovery, Syngene International, Thermo Fisher Scientific Inc., and WuXi AppTec. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.
Avoid missing out by staying informed – order our report now.
Find more Visiongain research reports on Pharma sector click on the following links:
Vaccine Sales Market Report 2022-2032
Veterinary Vaccines Market Report 2022-2032
Meningococcal Vaccines Market Report 2021-2031
Anti-infective Vaccines Market Report 2021-2031
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: oliver.davison@visiongain.com
About Visiongain
Visiongain is one of the fastest-growing and most innovative independent market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10 year forecasts, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs.
Contact:
Oliver Davison
PR at Visiongain Reports Limited
Tel: + 44 0207 336 6100
Email: oliver.davison@visiongain.com
Until the pandemic hit, Wall Street largely ignored the vaccine market. This year will show there’s more to jabs than fighting Covid-19.
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Phase 2b Data for EB01 in January 2023 Edesa Biotech, Inc. (NASDAQ:EDSA) is currently conducting a double blind, placebo controlled trial to evaluate the safety and efficacy of 2.0% EB01 cream in approximately 170 evaluable subjects in total suffering from chronic allergic contact dermatitis (ACD) ( NCT03680131 ).
The FCC has proposed a $299,997,000 fine against "the largest robocall firm" it has ever investigated.
Kinder Morgan (NYSE: KMI) is one of North America's leading energy infrastructure companies. It also has the largest carbon dioxide transportation capacity in the country. Carbon capture and storage is a potentially multitrillion-dollar market opportunity.
“Payment must be made in cash or legal tender,” noted the Labor Department after penalizing the offending Chick-fil-A.
If inflation and the markets have you fretting over your financial security, boost your income with one of these side hustles recommended by experts
The sweeping retirement legislation was approved by the Senate as part of an omnibus federal spending bill with broad support from the wealth management industry.
This week was going down as one to remember for Madrigal Pharmaceuticals (NASDAQ: MDGL). According to data compiled by S&P Global Market Intelligence, the biotech's shares were an eye-watering 350% higher week to date, as of Thursday's market close. Biotechs tend to pop like that when they report excellent clinical-trial results; such was the case with Madrigal.
Crude oil prices were on a roller coaster ride in 2022, going north of $130 in March amid the Russian invasion of Ukraine.
There are plenty of ways to minimize your tax liability and that’s especially true when you have worked hard to sock away retirement money. Tax advisors are constantly searching for new ways to avoid paying taxes on IRA withdrawals. There … Continue reading → The post How Can I Avoid Paying Taxes on IRA Withdrawals? appeared first on SmartAsset Blog.
The Secure 2.0 Act could become law as Congress finalizes a bill to avoid a government shutdown. That would mean changes for 401(k) retirement plans.
Crispr expects to make history in 2023 with a first-ever request in gene-editing technology by the same name, which could stoke shares.
With the New Year just a few days away, it’s time to start looking for the best portfolio choices going forward. This past year has been a mess for investors, and putting 2022’s bear market behind us will come as a relief – but finding solid choices for big gains will still require a high tolerance for risk. Fewer stock segments are more risky – or more potentially rewarding – than the penny stocks. Priced under $5 per share, these low-cost equities give investors a chance to double their money
Applied Molecular Transport Inc (NASDAQ: AMTI) announced topline Phase 2 results from the LOMBARD monotherapy trial for AMT-101 in biologic-naïve and experienced patients with moderate-to-severe ulcerative colitis (UC). The clinical remission (CR) rate in patients treated with AMT-101 monotherapy was 17.1% (12/70 patients) compared to a CR rate of 20.0% (7/35 patients) with placebo, which was above the company's baseline assumption for placebo CR rates based on published data in moderate-to-seve
(Reuters) -Used-car retailer CarMax Inc said on Thursday it was pausing some hiring, halting share buybacks and cutting expenses after reporting an 86% drop in third-quarter profit as the industry struggles to offload inventory amid waning demand. "CarMax is battling a used-vehicle recession," Evercore ISI analyst Michael Montani said, adding that pressure on wholesale sales intensified from the second quarter. In response to challenging industry conditions, CarMax said it slowed car buying in the third quarter and cut marketing and capital expenditures.
In this piece, we will take a look at the 15 biggest companies that offer pensions. For more companies, head on over to 5 Biggest Companies That Offer Pensions. Working for a large company comes with several benefits that are sought by those seeking stability, prestige, and career growth. One such benefit is a pension […]In this article, we discuss the 12 tech stocks with the biggest upside. If you want to read about some more tech stocks with the biggest upside, go directly to 5 Tech Stocks With Biggest Upside. Technology stocks are one of the hottest areas of the stock market and investors eagerly follow the latest developments […](Bloomberg) — Russia may reduce its oil output by 500,000-700,000 barrels a day in early 2023 in response to the Group of Seven’s price cap on the nation’s crude exports, according to Deputy Prime Minister Alexander Novak.Most Read from BloombergChina Estimates Covid Surge Is Infecting 37 Million People a DayChina Is Likely Seeing 1 Million Covid Cases, 5,000 Deaths a DaySBF’s $250 Million Bail Is One of the Largest in US History. It Doesn’t Mean He Has That MuchDonald Trump’s Taxes Reveal Big
In many Americans’ minds, the traditional retirement age is 65. But often people want to wrap up their career sooner than that. According to a 2021 report from Natixis Investment Managers, younger generations plan to retire earlier. Members of Generation Y … Continue reading → The post How to Retire at 64: Step-by-Step Plan appeared first on SmartAsset Blog.
U.S. Transportation Command — part of the U.S. Department of Defense — has awarded FedEx, UPS, and Polar Air Cargo firm fixed-price rates contracts that have an estimated total value of $2.24 billion.